updates from captivate: ibrutinib and venetoclax for cll
Published 4 years ago • 483 plays • Length 5:54Download video MP4
Download video MP3
Similar videos
-
2:21
captivate: ibrutinib and venetoclax in cll
-
2:14
positive results for captivate: ibrutinib and venetoclax for cll
-
1:23
captivate: fixed-duration ibrutinib plus venetoclax in patients with cll/sll
-
2:04
captivate: ibrutinib/venetoclax delivers high rates of umrd in cll
-
1:36
cll2-give trial: ibrutinib, venetoclax and obinutuzumab in patients with tp53-mutated cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
9:41
comparison of venetoclax-based treatments for cll - dr. benjamin heyman ash 2023
-
3:22
is cll curable today?
-
4:10
ibrutinib and venetoclax continue to provide benefits for patients with chronic cll and sll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:34
captivate study: outcomes in patients with umrd following cessation of ibrutinib plus venetoclax
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
2:39
clinical relevance of constitutive vla-4 activation in cll patients treated with ibrutinib
-
6:45
current research into drug treatments for cll - specifically ibrutinib, idelalisib and venetoclax
-
1:28
ibrutinib and venetoclax: a powerful combination in frontline and relapsed cll
-
17:23
updates in cll: key clinical trials in the frontline and r/r setting, pre-clinical data and mrd
-
2:06
effects of dose adjustment of first-line ibrutinib on real-world dosing patterns and outcomes in cll
-
1:37
causes & management of ibrutinib discontinuation in cll
-
3:00
five-year follow-up of the captivate trial: ibrutinib retreatment in patients with cll